<menu id="ssssw"><table id="ssssw"></table></menu>
  • <rt id="ssssw"><samp id="ssssw"></samp></rt>
  • <bdo id="ssssw"></bdo>
  • Your Good Partner in Biology Research

    Human Programmed Death Ligand-1(PD-L1/CD274) ELISA Kit

    • 中文名称:
      人程序性死亡因子配体1(PD-L1/CD274) ELISA Kit
    • 货号:
      CSB-E13644h
    • 规格:
      96T/48T
    • 价格:
      ¥3600/¥2500
    • 其他:

    产品详情

    • 产品描述:

      This Human CD274 ELISA Kit was designed for the quantitative measurement of Human CD274 protein in serum, plasma, tissue homogenates, cell lysates. It is a Sandwich ELISA kit, its detection range is 15.6 pg/mL-1000 pg/mL and the sensitivity is 3.9 pg/mL .

    • 别名:
      B7 H ELISA Kit; B7 H1 ELISA Kit; B7 homolog 1 ELISA Kit; B7-H1 ELISA Kit; B7H ELISA Kit; B7H1 ELISA Kit; CD 274 ELISA Kit; CD274 ELISA Kit; CD274 antigen ELISA Kit; CD274 molecule ELISA Kit; MGC142294 ELISA Kit; MGC142296 ELISA Kit; OTTHUMP00000021029 ELISA Kit; PD L1 ELISA Kit; PD-L1 ELISA Kit; PD1L1_HUMAN ELISA Kit; PDCD1 ligand 1 ELISA Kit; PDCD1L1 ELISA Kit; PDCD1LG1 ELISA Kit; PDL 1 ELISA Kit; PDL1 ELISA Kit; Programmed cell death 1 ligand 1 ELISA Kit; Programmed death ligand 1 ELISA Kit; RGD1566211 ELISA Kit
    • 缩写:
      CD274
    • Uniprot No.:
    • 种属:
      Homo sapiens (Human)
    • 样本类型:
      serum, plasma, tissue homogenates, cell lysates
    • 检测范围:
      15.6 pg/mL-1000 pg/mL
    • 灵敏度:
      3.9 pg/mL
    • 反应时间:
      1-5h
    • 样本体积:
      50-100ul
    • 检测波长:
      450 nm
    • 研究领域:
      Others
    • 测定原理:
      quantitative
    • 测定方法:
      Sandwich
    • 说明书:
    • 精密度:
      Intra-assay Precision (Precision within an assay): CV%<8%
      Three samples of known concentration were tested twenty times on one plate to assess.
      Inter-assay Precision (Precision between assays): CV%<10%
      Three samples of known concentration were tested in twenty assays to assess.
    • 线性度:
      To assess the linearity of the assay, samples were spiked with high concentrations of human PD-L1/CD274 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
       SampleSerum(n=4)
      1:1Average %90
      Range %80-101
      1:2Average %95
      Range %91-105
      1:4Average %98
      Range %90-107
      1:8Average %95
      Range %85-100
    • 回收率:
      The recovery of human PD-L1/CD274 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
      Sample TypeAverage % RecoveryRange
      Serum (n=5) 9689-104
      EDTA plasma (n=4)9590-107
    • 标准曲线:
      These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
      pg/mlOD1OD2AverageCorrected
      10002.274 2.174 2.224 1.965
      5001.940 1.854 1.897 1.638
      2501.450 1.355 1.403 1.144
      1250.927 0.955 0.941 0.682
      62.50.570 0.580 0.575 0.316
      31.20.422 0.417 0.420 0.161
      15.60.352 0.341 0.347 0.088
      00.253 0.265 0.259  
    • 本试剂盒所含材料:
      • A micro ELISA plate ---The 96-well plate has been pre-coated with an anti-human CD274 antibody. This dismountable microplate can be divided into 12 x 8 strip plates.
      • Two vials lyophilized standard ---Dilute a bottle of the standard at dilution series, read the OD values, and then draw a standard curve.
      • One vial Biotin-labeled CD274 antibody (100 x concentrate) (120 μl/bottle) ---Act as the detection antibody.
      • One vial HRP-avidin (100 x concentrate) (120 μl/bottle) ---Bind to the detection antibody and react with the TMB substrate to make the solution chromogenic.
      • One vial Biotin-antibody Diluent (15 ml/bottle) ---Dilute the Biotin-antibody.
      • One vial HRP-avidin Diluent (15 ml/bottle) ---Dilute the HRP-avidin solution.
      • One vial Sample Diluent (50 ml/bottle)---Dilute the sample to an appropriate concentration.
      • One vial Wash Buffer (25 x concentrate) (20 ml/bottle) ---Wash away unbound or free substances.
      • One vial TMB Substrate (10 ml/bottle) ---Act as the chromogenic agent. TMB interacts with HRP, eliciting the solution turns blue.
      • One vial Stop Solution (10 ml/bottle) ---Stop the color reaction. The solution color immediately turns from blue to yellow.
      • Four Adhesive Strips (For 96 wells) --- Cover the microplate when incubation.
      • An instruction manual

      显示更多

      收起更多

    • 本试剂盒不含材料:
      • A microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm.
      • An incubator can provide stable incubation conditions up to 37°C±5°C.
      • Centrifuge
      • Vortex
      • Squirt bottle, manifold dispenser, or automated microplate washer
      • Absorbent paper for blotting the microtiter plate
      • 50-300ul multi-channel micropipette
      • Pipette tips
      • Single-channel micropipette with different ranges
      • 100ml and 500ml graduated cylinders
      • Deionized or distilled water
      • Timer
      • Test tubes for dilution

      显示更多

      收起更多

    • 数据处理:
    • 货期:
      3-5 working days

    引用文献

    产品评价

    问答及客户评论

     常见问题解答
    Q:

    Which antibody is pre-coated onto a microplate? I would appreciate it if you could give me advice.

    A:
    Thanks for your inquiry.In this kit#CSB-E13644h,Human Programmed Death Ligand-1(PD-L1/CD274) ELISA Kit,2 antibodies are used:
    CaptureL:mouse monoclonal antibody;Detection:goat polyclonal antibody
    The plate is pre-coated and you can use it directly. Pls let me know if you have any further questions. Thank you.

    靶点详情

    • 功能:
      Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10).; The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy.
    • 基因功能参考文献:
      1. an HBV-pSTAT3-SALL4-miR-200c axis regulates PD-L1 causing T cell exhaustion PMID: 29593314
      2. hypothesized that an oncolytic poxvirus would attract T cells into the tumour, and induce PD-L1 expression in cancer and immune cells, leading to more susceptible targets for anti-PD-L1 immunotherapy PMID: 28345650
      3. multivariate Cox hazards regression analysis identified ALCAM and PD-L1 (both P < 0.01) as potential independent risk factors for primary diffuse pleural mesotheliomas PMID: 28811252
      4. miR-191-5p was identified to have negative correlation with PD-L1 expression and acted as an independent prognostic factor of OS in patients with colon adenocarcinoma. PMID: 30045644
      5. our findings suggest a regulatory mechanism of PD-L1 through data analysis, in vitro and vivo experiments, which is an important factor of immune evasion in GC cells, and CXCL9/10/11-CXCR3 could regulate PD-L1 expression through STAT and PI3K-Akt signaling pathways in GC cells. PMID: 29690901
      6. CD163(+)CD204(+) Tumor-associated macrophages possibly play a key role in the invasion and metastasis of oral squamous cell carcinoma by T-cell regulation via IL-10 and PD-L1 production. PMID: 28496107
      7. Results demonstrated that the expression of PDL1 in colorectal carcinoma tissue was significantly increased compared with the paracancerous tissue. Blocking PDL1 can inhibit tumor growth by activating CD4+ and CD8+ T cells involved in the immune response. PMID: 30272332
      8. miR-574-3p was identified to potentially regulate PD-L1 expression in chordoma, which inversely correlated with PD-L1. Positive PD-L1 expression on tumor cells was associated with advanced stages and TILs infiltration, whereas decreased miR-574-3p level correlated with higher muscle invasion, more severe tumor necrosis and poor patient survival. PMID: 29051990
      9. PD-L1 expression was detected in 69% of cases of primary melanoma of the vulva PMID: 28914674
      10. PD-L1 tumor cell expression is strongly associated with increased HIF-2alpha expression and presence of dense lymphocytic infiltration in clear cell renal cell carcinoma. PMID: 30144808
      11. Different Signaling Pathways in Regulating PD-L1 Expression in EGFR Mutated Lung Adenocarcinoma PMID: 30454551
      12. PD-L1, Ki-67, and p53 staining individually had significant prognostic value for patients with stage II and III colorectal cancer PMID: 28782638
      13. Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma PMID: 30050132
      14. Our results confirm and extend prior studies of PD-L1 and provide new data of PD-L2 expression in lymphomas PMID: 29122656
      15. Positive PD-L1 expression is indicative of worse clinical outcome in Xp11.2 renal cell carcinoma. PMID: 28522811
      16. PD-L1 expression in cancer cells is upregulated in response to DNA double-strand break. PMID: 29170499
      17. Targeting PD-L1 Protein is an efficient anti-cancer immunotherapy strategy. (Review) PMID: 30264678
      18. Suggest that PD-L1 may play a relevant role in metastatic spread and may be a candidate prognostic biomarker in cutaneous squamous cell carcinoma. PMID: 29742559
      19. PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters. PMID: 29874226
      20. SLC18A1 might complement other biomarkers currently under study in relation to programmed cell death protein 1/programmed cell death protein ligand 1 inhibition PMID: 30194079
      21. Low PDL1 expression is associated with mammary and extra-mammary Paget disease. PMID: 29943071
      22. Low PDL1 mRNA expression is associated with non-muscle-invasive bladder cancer. PMID: 29150702
      23. we found that in advanced stage NSCLC patients who received nivolumab, the C allele of PD-L1 rs4143815 and the G allele of rs2282055 were significantly associated with better ORR and PFS. This is the first report that PD-L1 SNP, which was thought to increase PD-L1 expression, is associated with a response to nivolumab. PMID: 28332580
      24. PD-L1 expression differs between the two components of lung ASCs. Given the complexity of lung ASCs, their treatment outcomes may be improved by administration of both EGFR TKIs and anti-PD-1/PD-L1 antibodies in cases where EGFR mutations are present and PD-L1 is overexpressed. PMID: 28387300
      25. IDO and B7-H1 expressions were observed in patients with pancreatic carcinoma tissues and are important markers for PC malignant progression PMID: 30029936
      26. There was higher programmed cell death protein ligand-1(PD-L1) expression in post-treatment EBV DNA-positive patients. Post-treatment positive EBV DNA status maybe a useful biomarker of worse outcomes in early stage -stage extranodal natural killer/T cell lymphoma. PMID: 30116872
      27. PD-L1 is a critical TTP-regulated factor that contributes to inhibiting antitumor immunity. PMID: 29936792
      28. Structural and functional analyses unexpectedly reveal an N-terminal loop outside the IgV domain of PD-1. This loop is not involved in recognition of PD-L1 but dominates binding to nivolumab, whereas N-glycosylation is not involved in binding at all. PMID: 28165004
      29. While mutational analysis appeared similar to that of older patients with OCSCC who lack a smoking history, a comparatively high degree of PD-L1 expression and PD-1/L1 concordance (P=0.001) was found among young female OCSCC patients. PMID: 28969885
      30. PD-L1 expression is predictive of survival in diffuse large B-cell lymphoma, irrespective of rituximab treatment. PMID: 29748856
      31. PD-L1 expression was augmented on CD8+ T cells in BALF of a patient with smoldering adult T-cell lymphoma and Pneumocystis jiroveci pneumonia. This suggested that the PD-1-PD-L1 system may suppress not only antitumor immunity but also host defense against pathogens and thereby allow establishment of chronic HTLV-1 infection and immunodeficiency. PMID: 28967040
      32. MUC1 drives PD-L1 expression in triple-negative breast cancer cells. PMID: 29263152
      33. Positive PD-L1 expression was found in 36.8% of inflammatory breast carcinoma (IBC) samples but was not significantly associated with the clinicopathologic variables examined. Worse overall survival (OS) was significantly associated with positive PD-L1, negative estrogen receptor, and triple-negative status. The 5-year OS rate was 36.4% for patients with PD-L1-positive IBC and 47.3% for those with PD-L1-negative. PMID: 29425258
      34. PD-L1 expression display a highly variable distribution in clear cell renal cell carcinomas and this particularity should be kept in mind when selecting the tumor samples to be tested for immunotherapy. PMID: 29661736
      35. Report relatively low level PD-L1 positivity in treatment-naive acinar prostatic adenocarcinoma. PMID: 30257853
      36. High PD-L1 expression is associated with pulmonary metastases in head and neck squamous cell carcinoma. PMID: 29937180
      37. these data suggest that DNA-damage signaling is insufficient for upregulating PD-L1 in normal human dermal fibroblasts PMID: 29859207
      38. High CD274 expression is associated with Oral Squamous Cell Carcinoma. PMID: 28669079
      39. This study provides important evidence of higher levels of agreement of PD-L1 expression in pulmonary metastasis compared with in multiple primary lung cancer, and high positivity of PD-L1 expression in pulmonary metastatic lesions with wild-type EGFR in an Asian population. PMID: 29254651
      40. High PD-L1 expression is associated with Mycobacterium avium complex-induced lung disease. PMID: 28169347
      41. PD-L1 expression in tumor-associated immune cells may be associated with a higher probability of clinical response to avelumab in metastatic breast cancer PMID: 29063313
      42. The expression of PDL1 was significantly increased following treatment with gefitinib. PMID: 29901173
      43. These results demonstrated that the IFNGinduced immunosuppressive properties of B7H1 in human BM and WJMSCs were mediated by STAT1 signaling, and not by PI3K/RACalpha serine/threonineprotein kinase signaling PMID: 29901104
      44. PD-1/PD-L1 expression is a frequent occurrence in poorly differentiated neuroendocrine carcinomas of the digestive system. PMID: 29037958
      45. High CD274 expression is associated with Epithelial Ovarian Cancer. PMID: 30275195
      46. Studied expression levels of CD274 molecule (PD-L1) in thymic epithelial tumors. Found PD-L1 expression level correlated with the degree of TET malignancy. PMID: 29850538
      47. Authors assessed PD-L1 expression in both tumor cells and tumor-infiltrating immune cells in the tumor specimens (complete histological sections, not tissue microarray). PMID: 28420659
      48. We conclude that a subgroup of advanced disease ovarian cancer patients with high grade tumors, expressing PD-L1, may be prime candidates for immunotherapy targeting PD-1 signaling PMID: 29843813
      49. PD-L1 expression is a prognostic factor related with poor survival among patients that developed non-small cell lung cancer. PMID: 29614306
      50. The inhibition of PTEN also reduced the cancer effects of CD4+ T cells on non-small cell lung cancer (NSCLC) cell lines following miR-142-5p downregulation. Therefore, our study demonstrated that miR-142-5p regulated CD4+ T cells in human NSCLC through PD-L1 expression via the PTEN pathway. PMID: 29767245

      显示更多

      收起更多

    • 亚细胞定位:
      Cell membrane; Single-pass type I membrane protein. Early endosome membrane; Single-pass type I membrane protein. Recycling endosome membrane; Single-pass type I membrane protein.; [Isoform 1]: Cell membrane; Single-pass type I membrane protein.; [Isoform 2]: Endomembrane system; Single-pass type I membrane protein.
    • 蛋白家族:
      Immunoglobulin superfamily, BTN/MOG family
    • 组织特异性:
      Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes.
    • 数据库链接:

      HGNC: 17635

      OMIM: 605402

      KEGG: hsa:29126

      STRING: 9606.ENSP00000370989

      UniGene: Hs.521989



    1v1周青梅郑宣木天寥
    <menu id="ssssw"><table id="ssssw"></table></menu>
  • <rt id="ssssw"><samp id="ssssw"></samp></rt>
  • <bdo id="ssssw"></bdo>